Deucravacitinib in Moderate to Severe Psoriasis : Clinical and Quality-of-Life Outcomes in a Phase 2 Trial
Thaçi, Diamant (University of Luebeck)
Strober, Bruce (Yale University)
Gordon, Kenneth B. (Medical College of Wisconsin)
Foley, Peter (The University of Melbourne)
Gooderham, Melinda (Queen's University and Probity Medical Research)
Morita, Akimichi (Nagoya City University)
Papp, Kim A. (Clinical Research and Probity Medical Research)
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau)
Menter, M. Alan (Baylor University Medical Center)
Colombo, Matthew J. (Bristol Myers Squibb)
Elbez, Yedid (Bristol Myers Squibb)
Kisa, Renata M. (Bristol Myers Squibb)
Ye, June (Bristol Myers Squibb)
Napoli, Andrew A. (Bristol Myers Squibb)
Wei, Lan (Bristol Myers Squibb)
Banerjee, Subhashis (Bristol Myers Squibb)
Merola, Joseph F. (Harvard Medical School)
Gottlieb, Alice B. (Icahn School of Medicine at Mount Sinai)
Universitat Autònoma de Barcelona

Date:	2022
Abstract:	Deucravacitinib is an oral, selective tyrosine kinase 2 inhibitor that demonstrated therapeutic benefit in a Phase 2 clinical trial of adults with moderate to severe plaque psoriasis. This analysis was designed to evaluate the effect of deucravacitinib on additional clinical and quality-of-life (QoL) outcomes and assess the relationship between these outcomes in adults with psoriasis. Post-hoc analysis of a 12-week Phase 2 trial was conducted for the three most efficacious dosage groups (3 mg twice daily, 6 mg twice daily, 12 mg once daily) and placebo. Investigator assessments for efficacy included Psoriasis Area and Severity Index (PASI), body surface area (BSA) involvement, and static Physician's Global Assessment; QoL was assessed using the Dermatology Life Quality Index (DLQI). Treatment responses and their associations were evaluated over time. Deucravacitinib elicited improvement versus placebo as early as Week 4 for most efficacy measures (including changes in absolute PASI and BSA), with efficacy trends observed from Week 2 to Week 12. Improvements in QoL, assessed by achievement of a DLQI overall score of 0/1 (no effect at all on patient's life), followed a pattern similar to deucravacitinib-related clinical outcomes over 12 weeks. Overall, patients with greater improvements in psoriasis-related clinical signs and symptoms also reported greater improvement in QoL. However, complete skin clearance was not required for achieving DLQI 0/1. Deucravacitinib treatment produced early response and similar trends in improvements across multiple efficacy assessments and QoL in moderate to severe plaque psoriasis. Deucravacitinib has the potential to become a promising new oral therapy for this condition. ClinicalTrials. gov identifier; NCT02931838. The online version contains supplementary material available at 10. 1007/s13555-021-00649-y. The online version contains supplementary material available at 10. 1007/s13555-021-00649-y.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Body surface area ; Humans ; Psoriasis ; Quality of life ; TYK2
Published in:	Dermatology and Therapy, Vol. 12 (january 2022) , p. 495-510, ISSN 2190-9172

DOI: 10.1007/s13555-021-00649-y
PMID: 35025062

16 p, 1.2 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles